Wall Street Zen Upgrades Biofrontera (NASDAQ:BFRI) to “Buy”

Biofrontera (NASDAQ:BFRI – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.

BFRI has been the topic of a number of other research reports. Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold”.

Get Biofrontera alerts:

Get Our Latest Analysis on Biofrontera

Biofrontera Price Performance

BFRI stock opened at $1.55 on Friday. Biofrontera has a 52-week low of $0.55 and a 52-week high of $1.66. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.78. The stock has a market cap of $23.02 million, a price-to-earnings ratio of -3.44 and a beta of 0.83. The business has a fifty day moving average of $1.30 and a two-hundred day moving average of $1.07.

Biofrontera (NASDAQ:BFRI – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. The business had revenue of $12.00 million for the quarter, compared to analyst estimates of $9.50 million. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. As a group, research analysts anticipate that Biofrontera will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its position in Biofrontera stock. Geode Capital Management LLC lifted its position in Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 54.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,677 shares of the company’s stock after buying an additional 23,074 shares during the quarter. Geode Capital Management LLC owned approximately 0.56% of Biofrontera worth $37,000 at the end of the most recent reporting period. 10.08% of the stock is currently owned by institutional investors.

About Biofrontera

(Get Free Report)

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.

Read More

• Five stocks we like better than Biofrontera
• Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
• 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
• Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
• As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.